Glenmark Pharmaceuticals has launched in India the first triple-drug fixed-dose combination (FDC) of the widely used Teneligliptin with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.
Glenmark’s Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita DM, Zita the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |